Pericardial effusion of HIV-infected patients - results of a prospective multicenter cohort study in the era of antiretroviral therapy by Lind, A et al.
480 november 10, 2011 Eu  Ro  PE  an JouR  nal of MEd  I  cal RE  sEaRcH
Abstract
Background:  Patients  with  human  immunodeficiency
virus (HIV) infection have an increased risk of cardio-
vascular diseases. Previous publications described peri-
cardial effusion as one of the most common HIV-as-
sociated  cardiac  affiliations.  the  aim  of  the  current
study was to investigate if pericardial effusion still has
a relevant meaning of HIV-infected patients in the era
of antiretroviral therapy.
Methods:  the  HIV-HEaRt  (HIV-infection  and
HEaRt disease) study is a cardiology driven, prospec-
tive and multicenter cohort study. outpatients with a
known  HIV-infection  were  recruited  during  a  20-
month period in a consecutive manner from septem-
ber 2004 to May 2006. the study comprehends classic
parameters  of  HIV-infection,  comprising  cd4-cell
count  (cluster  of  differentiation)  and  virus  load,  as
well as non-invasive tests of cardiac diseases, including
a thorough transthoracic echocardiography.
Results:  802  HIV-infected  patients  (female:  16.6%)
with a mean age of 44.2 ﾱ 10.3 years, were included.
duration of HIV-infection since initial diagnosis was
7.6 ﾱ 5.8 years. of all participants, 85.2% received an-
tiretroviral therapy. Virus load was detectable in 34.4%
and  cd4  -  cell  count  was  in  12.4%  less  than  200
cells/ﾵl. Pericardial effusions were present in only two
patients of the analysed population. none of the par-
ticipants had signs of a relevant cardiovascular impair-
ment by pericardial effusion. 
Conclusions:  our  results  demonstrate  that  the  era  of
antiretroviral therapy goes along with low rates of peri-
cardial effusions in HIV-infected outpatients. our find-
ings are in contrast to the results of publications, per-
formedbefore the common use of antiretroviral therapy.
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IntRoductIon
HIV-infection is often associated with cardiac disor-
ders [1]. nevertheless, cardiac involvement in this pa-
tient population was frequently underdiagnosed or at-
tributed  incorrectly  to  other  non-cardiac  disease
processes [2].
In particular symptoms, such as fatigue or reduced
exercise intolerance, are common in this patient popu-
lation and could belong to chronic cardiac disorders,
such as pericardial effusion. In fact, previous studies
described, that a pericardial effusion is present in up
to 11% of cases[3] and, therefore, it was supposed to
be one of the most common cardiac disorder in HIV-
infected subjects [4].
However, the development of antiretroviral thera-
peutics dramatically changed the natural history of the
HIV-infection. although today most of the patients
infected with the HI-virus receive antiretroviral thera-
py, there is still a lack of knowledge about its effects
on cardiac disorders and in particular the extend of
pericardial effusion. 
the  current  study  investigates  the  frequency  of
pericardial effusion and gives an answer to the ques-
tion, if it still is one of the main relevant HIV-associat-
ed cardiac diseases in the era of antiretroviral therapy.
MEtHods
data from the HIV-HEaRt (HIV-infection andHEaRt
disease)  study  were  used  for  the  following  analyses.
this study is a cross-sectional study conducted as part
of the HIV-HEaRt prospective study designed to de-
fine the prevalence and natural history of cardiovascu-
lar diseases in HIV-infected individuals with and with-
out antiretroviral therapy. all relevant facts of the HIV-
HEaRt study, including design, inclusion and exclu-
sion criteria, diagnostic techniques and questionnaires,
have been published previously [5]. In short, main as-
pects for the present analyses are described as follows: 
Patients: during a recruiting time of 20 month from
september 2004 to May 2006, more than 800 consecu-
tive patients were recruited. all patients had to fulfil
the inclusion criteria, in particular a known infection
with the human immunodeficiency virus and a stable
health condition within 4 weeks before inclusion. fur-
thermore,  an  appropriate  written  informed  consent
and an age over 18 years were requested for inclusion
in this prospective trial. Patients were recruited from a
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2) Lind##_Umbruchvorlage  12.10.11  12:52  Seite 480multicenter network, which has been founded for the
present study. the network combined physicians spe-
cialized in the diagnostic and treatment of HIV-infect-
ed patients and contained all regional forms of out-pa-
tient  medical  care  institutions,  medical  practices,
health care centers, and outpatient departments.
Study  protocol:  the  study  protocol  included  a  stan-
dardized assessment of medical history and physical
examination. Blood was drawn for comprehensive lab-
oratory tests. furthermore, non-invasive tests of the
present study were performed during the initial visit.
these tests included subsequent heart rate and blood
pressure  measurements,  resting  electrocardiogram
(EcGs),  a  functional  capacity  test  (six-minute  walk
test), and transthoracic echocardiography. 
Echocardiography was performed under stable con-
ditions in a quiet environment and according to a pre-
viously  defined  standardized  operation  protocol.  to
get the best cardiac view, the patient laid on the left
side. Echocardiography protocol included a paraster-
nal, apical, substernal echocardiography of the heart.
the presence of pericardial effusion was documented
and separation of pericardium was measured in at the
end of diastole at the right- and left ventricular cham-
bers of the heart. the examinations were performed
in accordance with the standard operating procedures
(soPs) of the German Heart failure network and the
Esc-Guidelines. If a pericardial effusion was identi-
fied in 2d- Echocardiography or M-Mode- Echocar-
diography the size was graded as: (1) small (echo-free
space in diastole <10 mm), (2) moderate (10–20 mm),
(3) large (>20 mm), or (4) very large (≥20 mm and
compression  of  the  heart)  corresponding  to  the
Horowitz class B to d [6].
Ethical Considerations and Statistics: the protocol was
approved by the Institutional Review Board of our cen-
ter and was performed in accordance with institutional
guidelines and the declaration of Helsinki. statistical
analysis was performed by the statistical package sPss
Version 17.0 (sPss Inc.). Variables were presented as
mean  and  standard  deviation.  In  addition,  median,
whole range and interquartile range (IQR) from 25%-
75% quartile are obtained for selected variables.
REsults
802 participants (83.4% male) were analysed for the
present study. the mean age in this population was
44.2 ﾱ10.3 years (Median: 43y). at the date of initial
HIV-diagnosis, the age of the participants was 36.5 ﾱ
10.7 years. Hence, the HIV-infection was diagnosed
for 91.6 ﾱ 69 months (= 7.6 ﾱ 5.8 years) when pa-
tients were included into the study. concerning the
severity of the disease, more than 30% of the includ-
ed persons had a status c (aIds level) in the cdc-
classification  [7].  further  information  about  demo-
graphics and HIV-specific parameters are presented in
table 1.
a number of patients presented with clinical symp-
toms suspicious for pericardial effusion. In particular
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Fig. 1. Pericardial effusion of an asymptomatic HIV-infected
subject.  the  pericardial  effusion  was  first  identified  by
echocardiography in the present study.  
Table 1. demographics and HIV-specific variables.
Patient characteristics Mean ﾱ sd
age (years) 44.2 ﾱ 10.3
Gender (n (%Male)) 669 (83.4)
BMI (kg/m2) 24.1 ﾱ 3.7
Heart rate at rest (beats/ min) 70.6 ﾱ 12.2
systolic blood pressure at rest (mm Hg) 128.4 ﾱ 20.7
diastolic blood pressure at rest (mm Hg) 83.2 ﾱ 12.4
HIV-specific variables
duration of HIV infection (month) 91.6 ﾱ 69
Mean cd4 cell count (cells/mm3) 508.8 ﾱ 300.6
cd4/cd8 ratio 0.62 ﾱ 0.53
Mean HIV-1Viral load (Rna copies/ml) 33419 ﾱ 71827
Way of infection (n (%))
• MsM 477 (59.5)
• Heterosex. contact 163 (20.3)
• IVda 75 (9.4)
• Epidemic areas 56 (7.0)
• Blood transfusion 13 (1.6)
Patients receiving aRt (% of all) 85.2 %
Patients antiretroviral therapy naive (% of all) 10.8 %
Patients in treatment interruption (% of all) 4.0 %
HIV specific treatment (% of aRt)
• nnRtI 45.7 %
• nRtI 96.8 %
• PI 48.5 %
Hepatitis B (% of all) 30.5 %
Hepatitis c (% of all) 10.5 %
abbreviations: BMI - body mass index, Rna - Ribonucleic
acid, MsM – Men who have sex with Men, IVda - intra-
venous drug abuse, aRt - anti-retroviral therapy, nnRtI -
non-nucleoside reverse transcriptase inhibitors; nRtI - nu-
cleoside  reverse  transcriptase  inhibitors;  PI  -  protease  in-
hibitors. 
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cise-induced dyspnoea. furthermore 29.4% exhibited
a reduced physical activity (<350m in 6 minute walk
test). other signs of pericardial effusion, that could be
a result of a reduction in right heart filling, such as
oedema were seen in 33 (4.1%) participants. 
In addition to clinical symptoms, patients also ex-
hibited cardiovascular parameters, that can be associat-
ed with pericardial effusion or tamponade, such as an
increased heart rate of more than 90 beats per minute
(6.2% of patients) or a low systolic blood pressure of
less than 100 mmHg (4.3% of patients).
on the other hand the included patient population
also exhibited HIV-associated and non HIV-associated
diseases predisposing for the development of pericar-
dial effusion. one of the main aspects for the develop-
ment of pericardial effusion is infectious disease. While
all included subjects had a chronic infection with the
HI-virus,  co-infections  with  Hepatitis  B  and  c  were
also common (30.5% and 10.5%, respectively). other
diseases, that could induce pericardial effusion, were re-
nal dysfunction demonstrated by a creatinine value of
more than 1.3 mg/dl in 6.2% of analysed patients. liv-
er cirrhosis was seen in 1.3% of all analysed patients.
We could even see a number of participants com-
bining a severe cdc-classification with symptoms and
diseases suggestive for development of pericardial ef-
fusion.  However the rate of the subjects who actually
developed a pericardial effusion was rather small. only
in two of the 802 (0.25 %) HIV-infected patients peri-
cardial  effusion  could  be  seen  by  echocardiography.
none of these patients exhibited tamponade or signs
of cardiovascular impairment such as swinging heart. 
the two patients identified with pericardial effusion
were male subjects at the age of 41 and 55 years, both
receiving antiretroviral therapy. small pericardial effu-
sion (<10mm) corresponding to type B pericardial ef-
fusion[8] could be identified on both patients. no clin-
ical signs of pericardial tamponade [6] like oedema as
a sign for right heart failure, hypotension, tachycardia,
pulsus paradoxus could be documented. Both patients
presented  with  normal  left  ventricular  ejection  frac-
tion. In the younger patient HIV-infection (cdc stage
c3), liver cirrhosis, co-infection with Hepatitis B and
c, chronic renal failure grade 2 [9] was present and im-
proved  the  assumption  of  extra-cardiac  reasons  for
pericardial effusion. follow-up data of this patient is
not  available.  the  other  HIV-positive  patient  (cdc
stage B3) presenting with pericardial effusion had no
other known diseases. We therefore assume that HIV-
infection was the cause for the documented small peri-
cardial effusion. In the 2-year follow up of the second
patient  no  remaining  pericardial  effusion  could  be
documented.
dIscussIon
our results demonstrate a low rate of pericardial effu-
sion in HIV-infected patients in the era of antiretrovi-
ral therapy. this finding is in contrast to previously
published results. Heidenreich et al. stated in 1995 that
pericardial effusion is known to be common among
patients infected with HIV [3]. Velasquez et al. even
went one step further and declared this cardiac affilia-
tion to be the most common cardiovascular manifesta-
tion of HIV infection [10].
the assumptions of the above authors were based
on a variety of echocardiographic studies on HIV-in-
fected subjects, mostly performed in the pre-HaaRt
(Highly active anti-Retroviral therapy) era between
1985 and 1995. the prevalence of pericardial effusion
rates published in three major trials range from 5% to
45% in different HIV-infected patient collectives [11-
13]. despite different inclusion criteria and different
patient collectives, one of them only including patients
with aIds [13], they illustrate the tremendous impact
on morbidity of pericardial effusion in HIV-infected
individuals.
also  in  developing  countries  a  high  incidence  of
pericardial effusion was described [14]. Pericardial ef-
fusions in these patient collectives were mainly seen in
combination  with  tuberculosis,  which  is  associated
with an increased mortality as previously described by
Mayosi et al. [15, 16].
In our patients presenting with pericardial effusion
we could not identify a specific bacterial infection be-
ing the reason for pericardial effusion. also other pre-
viously described reasons like neoplasm or a cardiac
trauma [17-20] could be ruled out in our patients. one
patient presented with liver cirrhosis based on hepati-
tis infection and renal disorder which lead to the sug-
gestion that these diseases were responsible for devel-
opment of pericardial effusion rather than the HIV-
Infection.
although  antiretroviral  drugs  might  diminish  the
incidence of pericardial effusion due to opportunistic
infections, other causes for the development of this
cardiac disorder might have become more frequent. In
particular, the improvement of the immune defence
by the use of antiretroviral drugs could induce pericar-
dial effusions in the context of an immune reconstitu-
tion inflammatory syndromes [21]. this was not the
case in our study, however.
the reason, why the rate of pericardial effusion is
significantly reduced in the era of antiretroviral thera-
py is yet unknown and could not definitively be an-
swered by our work. nevertheless, it seems to be obvi-
ous,  that  the  effective  blockade  of  virus  replication
and a reduced rate of opportunistic infections might
have major effects on the low pericardial effusion rate.
lIMItatIons of tHE study
there are limitations due to the single cross-sectional
design of the study. cross-sectional studies are carried
out at one time point or over a short period of time
and are usually conducted to estimate the prevalence of
the outcome of interest for a given population. In the
case of longer lasting diseases like HIV, any risk factor
might be underrepresented among those with the dis-
ease. Hence the data have to be addressed carefully. 
due  to  a  high  specificity  (100%)  and  sensitivity
(94%)  [8,  22]  transthoracic  echocardiography  is  rec-
ommended  for  detection  of  pericardial  effusion.[6]
the present study was performed by a trained staff
according to a standardized echocardiography proto-
col and demonstrated a very low intra-observer vari-
ability. However in patients with poor echo window,
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optimal. this was not the case in our patient collec-
tive. therefore, we believe that the present results are
reliable and reflect reality. 
another limitation might be the exclusion of hospi-
talized patients. In fact, a hospitalized group of HIV
patients might have lead to an increased rate of peri-
cardial effusion. However, the topic of our work was
to  analyse  the  impact  of  pericardial  effusion  in  the
group of outpatients that is the largest cohort of indi-
viduals in HIV-community since an effective antiretro-
viral therapy was developed. 
conclusIon
summarizing our data, pericardial effusion in HIV-in-
fected patients is less frequent in the era of antiretro-
viral drug therapy, compared to the pre-HaaRt era.
clinical symptoms such as dyspnoea, exercise intoler-
ance or oedema are suspicious for pericardial effusion
and should lead to further investigation by transtho-
racic echocardiography being a reliable screening tool.
this should be done in any patient suffering from the
above symptoms independent from an infection with
the HI-Virus. 
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